logo-loader
HealthPharma & Biotech
Constellation Pharmaceuticals

Constellation Pharmaceuticals presents poster on studies involving drug therapy to treat bladder cancer

Patricia Keller, senior scientist at Constellation, made the poster presentation at the American Association for Cancer Research in Denver

bladder
The poster discusses results of Constellation’s work with its second-generation EZH2 inhibitor CPI-0209 in bladder cancer models

Constellation Pharmaceuticals Inc (NASDAQ:CNST) fell into the red Monday on the same day the company presented a poster on studies involving the company’s drug therapy to treat bladder cancer.

The Cambridge, Massachusetts-based company’s stock recently traded at $8.99 a share, down 15.4% on higher-than-average volume.

Patricia Keller, senior scientist at Constellation, made the poster presentation titled "targeting epigentic dysregulation in bladder cancer through inhibition of EZH2" at the Bladder Cancer: Transforming the Field meeting of the American Association for Cancer Research in Denver.

The poster discusses results of Constellation’s work with its second-generation EZH2 inhibitor CPI-0209 in bladder cancer models, exploring whether ARIDA mutation status affected responsiveness to CPI-0209 treatment, according to a statement. 

ARID1A, a protein that is a key component of the SWI/SNF chromatin remodeling complex, is mutated in about 25% of muscle-invasive bladder cancers, the company said.

Constellation used CPI-0209 in long-term phenotypic growth assays in a panel of 21 bladder cancer cell lines, demonstrating preferential treatment sensitivity that correlated with increased cell death in cell lines harboring ARID1A mutations. Transcriptional profiling after CPI-0209 treatment showed widespread activation of EZH2 target gene expression, the company said. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Constellation Pharmaceuticals

Price: $7.96

Market: NASDAQ
Market Cap: $205.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Premier Oil farms into 88 Energy's conventional acreage in...

Headlines from the Proactive UK newsroom. Premier Oil (LON:PMO) has emerged as the farm-in partner for 88 Energy’s (LON:88E) conventional acreage in Alaska.  Premier has signed a sale and leaseback agreement for 60% of Area A on the North Slope Basin.  Elsewhere, Premier’s also...

23 minutes ago

2 min read